Start
Entdecken
nav.journalClub
Trends
Mehr
synapse
⌘+K
Sprache
Deutsch
Deutsch
Combining onabotulinumtoxina and CGRP monoclonal antibodies in chronic migraine: A systematic review | Synapse
March 3, 2026
Combining onabotulinumtoxina and CGRP monoclonal antibodies in chronic migraine: A systematic review
AK
Adinda Aisya Kamila
TC
Timothy Chong
TW
Tissa Wijeratne
The University of Melbourne
Key Points
Combining onabotulinumtoxina and CGRP monoclonal antibodies shows improved outcomes in chronic migraine treatment.
Meta-analysis of various studies reveals significant reductions in headache frequency when using both therapies together.
Observational analysis of treatment effects highlights efficacy in patients unresponsive to standard treatments.
Results suggest further investigation into this dual therapy is warranted for chronic migraine management.
Mark Helpful
Like
Save
Bookmark
Relay
Share
Mark Helpful
Like
Save
Bookmark
Relay
Share
Cite This Study
Copy
Kamila et al. (Mon,) studied this question.
synapsesocial.com/papers/69a75f50c6e9836116a2a9a7
https://doi.org/https://doi.org/10.1016/j.jns.2025.124179